Molbio Diagnostics shares made a strong market entry, listing at ₹980—a 21.44% premium over the issue price of ₹807—despite prevailing bearish sentiment in the broader stock market.
- Listed at ₹980 on BSE/NSE, representing a 21.44% gain over the issue price.
- The IPO was oversubscribed by more than 70 times overall.
- Funds will be utilized for R&D infrastructure and plant machinery expansion.
On Monday, August 17, Molbio Diagnostics made a triumphant debut on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). In a striking defiance of the weak overall stock market sentiment, the shares listed at ₹980, marking a significant 21.44% premium over the initial issue price of ₹807. However, the initial surge was followed by immediate profit-booking, which saw the stock settle slightly lower at ₹925.80 on the BSE and ₹926.35 on the NSE.
The listing performance significantly outperformed the Grey Market Premium (GMP) expectations. On Monday morning, the GMP stood at ₹120, suggesting a potential listing price of around ₹927 (a 15% premium). The actual debut at ₹980 indicates higher-than-anticipated institutional and retail demand.
IPO Structure and Financials
The Molbio Diagnostics IPO was structured as a hybrid offering, consisting of a fresh issue of 24,80,246 shares worth ₹200 crore and an Offer for Sale (OFS) of 91,66,000 shares valued at ₹739.70 crore.
| Parameter | Details |
|---|---|
| Issue Price | ₹807 |
| Listing Price | ₹980 |
| Total Subscription | 70x+ |
| Retail Subscription | 13x |
Why This Matters
BozokMedia analysis shows that the strong debut of Molbio Diagnostics highlights a critical investor appetite for specialized healthcare technology. The company's rapid revenue growth—climbing from ₹836.56 crore in FY24 to ₹1,445.69 crore in FY26—positions it as a high-growth entity in the point-of-care (POC) diagnostics space, which is becoming pivotal for global pandemic preparedness and chronic disease management.
"A 21% premium in a bearish market is a strong signal of confidence in the company's scalable business model and technological edge."
The company plans to deploy the net proceeds from the fresh issue to establish a state-of-the-art research and development facility and a center of excellence via its subsidiary, Bigtec. Furthermore, capital will be allocated toward upgrading plant and machinery at its Goa (Unit I & II) and Visakhapatnam facilities to scale production capacity.
The issue, which was open from August 10 to August 12, saw massive interest, particularly in the retail segment which was booked 13 times. The process was managed by lead managers including Kotak Mahindra Capital, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors, with KFin Technologies serving as the registrar.
Frequently Asked Questions
1. What was the listing price of Molbio Diagnostics?
The shares listed at ₹980 on both the BSE and NSE, which is a 21.44% premium over the issue price of ₹807.
2. How will the company use the IPO proceeds?
The funds will be used for R&D infrastructure, establishing a center of excellence via Bigtec, and purchasing machinery for its Goa and Visakhapatnam units.
